Species:
Mice (CD-1, C57BL/6, etc.), rats (Sprague-Dawley, Wistar, Wistar-Han, etc.), Lakeview Golden (LVG) Syrian hamsters, Guinea pigs
Administration Routes:
Oral (PO), intravenous (IV bolus, infusion), intraarterial (IA), intramuscular (IM), intraperitoneal (IP), intratracheal (IT), subcutaneous (SC), transdermal (TD), oropharyngeal aspiration (OA), intrarectal (IR), intranasal (IN), single or multiple doses
Surgical Techniques:
Bile-duct cannulation (BDC), jugular cannulation (JVC), portal vein cannulation (PVC), carotid artery cannulation (CAC), JVC/CAC, JVC/PVC
Biological Matrices:
Blood, plasma, serum, bile, urine, feces, cerebrospinal fluid (CSF), bone marrow, tissue (liver, brain, kidney, etc.) or tumor specimen
Mouse PK: Serial bleeding
Cassette-dosing (up to 5-in-1)
Excretion pathways
Turnaround Time:
5-10 working days for small molecules
5-10 working days of bioanalysis for large molecules (the entire study turnaround time is dependent on in-life sampling period)
Species:
Dogs: In-house dog colonies: 48 Beagle dogs (Shanghai site) and 68 Beagle dogs (Wuxi site)
Monkeys: In-house NHP colony: 96 Cynomolgus monkeys (Rhesus monkeys also available) (Wuxi site)
New Zealand rabbits, Bama mini-pigs, ferrets, etc. (Wuxi site)
Administration routes: IV bolus, IV infusion, PO (liquid, capsule, tablet), IM, SC, dog knee joint administration, rabbit vitreous injection, minipig / rabbit patch administration; single dose or cassette dose (up to 5-in-1)
Dosing design: Crossover or non-crossover
Fast or fed (food effect)
Expanded biological matrices sampling: blood, plasma, serum, urine, feces, serial CSF sampling from dogs and monkeys
Excretion pathways
PK/PD evaluation
Turnaround time: 5 - 10 working days after receiving test compounds (non-naive animals & non-crossover dosing design)
Maximum Toleration Dose (MTD)
Dose Ranging Finding (DRF)/Toxicokinetics (TK) (7-, 14- and 28-days)
Clinical observation, clinical pathology (hematology, serum chemistry and coagulation), and histopathology (samples analyzed by the partners)
PK parameters
Bioavailability
Tissue distribution
Dose proportionality
Excretion pathways: biliary vs urinary
Vehicle selection
Blood Brain Barrier (BBB)
Drug-drug interaction
PD Biomarkers
Capacity
100 IV/PO PK Studies/Week
Pre-formulation screening
~2500 Compounds/Year